Incyte’s Phase 3 frontMIND trial shows tafasitamab plus lenalidomide with R‑CHOP significantly improves progression‑free survival in high‑risk DLBCL and HGBL, supporting global regulatory submissions following ASCO 2026 and The Lancet publication.
Written By: Farha Farheen, PharmD
Reviewed By: Pharmacally Editorial Team
Incyte has reported positive Phase 3 results from the pivotal frontMIND trial (NCT04824092), showing that tafasitamab (Monjuvi/Minjuvi) combined with lenalidomide and R-CHOP reduced the risk of disease progression or death by 25% compared with R-CHOP alone in adults with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL).
The findings were presented at the 2026 ASCO Annual Meeting and published simultaneously in The Lancet.
Study Design
The randomized, double-blind, placebo-controlled study enrolled 899 adults aged 18–80 years with untreated high-risk disease, defined by an International Prognostic Index (IPI) score of 3–5 or an age-adjusted IPI score of 2–3. Patients received either tafasitamab plus lenalidomide with R-CHOP (Tafa-Len-R-CHOP) or R-CHOP alone.
Tafasitamab is a CD19-targeting monoclonal antibody that enhances immune-mediated B-cell killing through antibody-dependent cellular cytotoxicity and phagocytosis. The study evaluated whether adding tafasitamab and lenalidomide to standard frontline R-CHOP could improve outcomes in high-risk patients.
Efficacy Outcomes
After a median follow-up of 35.2 months, Tafa-Len-R-CHOP significantly reduced the risk of progression or death by 25% versus R-CHOP alone (HR 0.75; p=0.0194). Progression-free survival improved from 62.9% to 71.1% at two years and from 60.7% to 67.3% at three years.
The regimen also significantly improved event-free survival (HR 0.79; p=0.0260). Interim overall survival analysis showed a favorable trend (HR 0.85), although statistical significance has not yet been reached and follow-up remains ongoing.
Incyte noted that outcomes for high-risk DLBCL have remained largely unchanged for decades despite R-CHOP serving as the frontline standard of care, leaving many patients at risk of relapse or disease progression.
Subgroup Consistency
Progression-free survival benefits were observed across prespecified subgroups, including patients with centrally confirmed lymphoma subtypes and both activated B-cell-like (ABC) and germinal center B-cell-like (GCB) molecular subtypes. Similar trends were also reported across age groups and IPI risk categories.
Safety Profile
Tafa-Len-R-CHOP was generally well tolerated, with a safety profile consistent with the known effects of the individual therapies. Grade 3 or higher adverse events occurred more frequently with the combination than with R-CHOP alone (86.7% vs 76.1%), primarily anemia, thrombocytopenia, and neutropenia.
Treatment discontinuation rates were similar between groups (5.2% vs 5.4%), indicating that the additional toxicity was manageable without compromising delivery of the R-CHOP backbone. Fatal treatment-emergent adverse events occurred more frequently with Tafa-Len-R-CHOP (5.9% vs 3.8%), although overall deaths were lower than with R-CHOP alone (18.5% vs 21.7%).
Regulatory Outlook
Steven Stein, M.D., Executive Vice President, Chief Medical Officer and Head of Late-stage Development at Incyte, said the frontMIND findings support global regulatory submissions for tafasitamab and lenalidomide in combination with R-CHOP as a potential new first-line treatment option for patients with high-risk DLBCL and HGBL.
Tafasitamab is already approved in multiple markets for relapsed or refractory B-cell lymphomas, including DLBCL and follicular lymphoma. If approved, the frontMIND indication would move the CD19-targeting antibody into the frontline setting, significantly expanding its role in B-cell lymphoma treatment.
Reference
About the Writer
Farha Farheen, PharmD (LinkedIn) is a pharmacy professional with a strong interest in pharmacovigilance and clinical research. She has completed her Doctor of Pharmacy (Pharm.D) along with her internship as a Clinical Pharmacist. She has hands-on experience in adverse drug reaction (ADR) reporting, safety data documentation, and pharmacovigilance workflows, and is proficient in using VigiFlow. She is also a patent holder for an antibacterial formulation enriched with bioactive substances, granted by the German Patent and Trademark Office.